RT Journal Article
SR Electronic
T1 Remdesivir induced viral RNA and subgenomic RNA suppression, and evolution of viral variants in SARS-CoV-2 infected patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.18.20230599
DO 10.1101/2020.11.18.20230599
A1 Boshier, Florencia A.T.
A1 Pang, Juanita
A1 Penner, Justin
A1 Hughes, Joseph
A1 Parker, Matthew
A1 Shepherd, James
A1 Alders, Nele
A1 Bamford, Alasdair
A1 Grandjean, Louis
A1 Grunewald, Stephanie
A1 Hatcher, James
A1 Best, Timothy
A1 Dalton, Caroline
A1 Bynoe, Patricia Dyal
A1 Frauenfelder, Claire
A1 Köeglmeier, Jutta
A1 Myerson, Phoebe
A1 Roy, Sunando
A1 Williams, Rachel
A1 The COVID-19 Genomics UK (COG-UK) consortium
A1 Thomson, Emma C
A1 de Silva, Thushan I
A1 Goldstein, Richard A.
A1 Breuer, Judith
YR 2020
UL http://medrxiv.org/content/early/2020/11/20/2020.11.18.20230599.abstract
AB While changes in SARS-CoV-2 viral load over time have been documented, detailed information on the impact of remdesivir and how it might alter intra-host viral evolution is limited. Sequential viral loads and deep sequencing of SARS-CoV-2 recovered from the upper respiratory tract of hospitalised children revealed that remdesivir treatment suppressed viral RNA levels in one patient but not in a second infected with an identical strain. Evidence of drug resistance to explain this difference was not found. Reduced levels of subgenomic (sg) RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication that is independent of viral RNA levels. Haplotype reconstruction uncovered persistent SARS-CoV-2 variant genotypes in four patients. We conclude that these are likely to have arisen from within-host evolution, and not co-transmission, although superinfection cannot be excluded in one case. Sample-to-sample heterogeneity in the abundances of variant genotypes is best explained by the presence of discrete viral populations in the lung with incomplete population sampling in diagnostic swabs. Such compartmentalisation is well described in serious lung infections caused by influenza and Mycobacterium tuberculosis and has been associated with poor drug penetration, suboptimal treatment and drug resistance. Our data provide evidence that remdesivir is able to suppress SARS-CoV-2 replication in vivo but that its efficacy may be compromised by factors reducing penetration into the lung. Based on data from influenza and Mycobacterium tuberculosis lung infections we conclude that early use of remdesivir combined with other agents should now be evaluated.Summary Sentence Deep sequencing of longitudinal samples from SARS-CoV-2 infected paediatric patients identifies evidence of remdesivir-associated inhibition of viral replication in vivo and uncovers evidence of within host evolution of distinct viral genotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. This work was supported by The John Black Charitable Foundation and the UCLH and GOSH NIHR biomedical research centres. JP is supported by the Rosetrees Foundation and FTB by a Wellcome Trust Collaborative Award to JB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Great Ormond Street Hospital (Clinical Audit Number #2857) and PHE Research Ethics and Governance Group (REGG) (R&D NR0195).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available upon request.